标题
Shedding New Light
作者
关键词
-
出版物
PEDIATRIC CLINICS OF NORTH AMERICA
Volume 70, Issue 5, Pages 937-950
出版商
Elsevier BV
发表日期
2023-09-12
DOI
10.1016/j.pcl.2023.05.007
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome
- (2022) Taizo A. Nakano et al. JOURNAL OF PEDIATRICS
- MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
- (2022) Peter M K de Blank et al. NEURO-ONCOLOGY
- Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome
- (2022) Anne Leegaard et al. European Journal of Medical Genetics
- Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment
- (2022) Leah J. Kershner et al. JCI Insight
- Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
- (2021) Michael J. Fisher et al. NATURE MEDICINE
- Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)
- (2021) Michael J. Fisher et al. ACTA NEUROPATHOLOGICA
- FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
- (2021) Denise Casey et al. CLINICAL CANCER RESEARCH
- NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
- (2021) Brian D. Weiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020
- (2021) Jace P. Landry et al. JAMA Network Open
- MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
- (2021) Anja Harder Biomarker Research
- Recurrent NF1 gene variants and their genotype/phenotype correlations in patients with Neurofibromatosis type I
- (2021) Matteo Riva et al. GENES CHROMOSOMES & CANCER
- Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
- (2021) Eric Legius et al. GENETICS IN MEDICINE
- Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
- (2021) Karin S. Walsh et al. Neurology-Genetics
- Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants
- (2021) Hildegard Kehrer-Sawatzki et al. HUMAN GENETICS
- The structure of neurofibromin isoform 2 reveals different functional states
- (2021) Andreas Naschberger et al. NATURE
- The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1
- (2021) Christopher J. Lupton et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference
- (2020) Roger J Packer et al. NEURO-ONCOLOGY
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- (2020) Andrea M. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
- (2020) Laura J. Klesse et al. ONCOLOGIST
- A molecular basis for neurofibroma-associated skeletal manifestations in NF1
- (2020) Yun Ma et al. GENETICS IN MEDICINE
- Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation
- (2020) Justin D. Bobyn et al. JOURNAL OF ORTHOPAEDIC SCIENCE
- Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR
- (2020) Wupeng Yan et al. Cell Reports
- Are Some Randomized Clinical Trials Impossible?
- (2020) Jonathan J. Rios et al. JOURNAL OF PEDIATRIC ORTHOPAEDICS
- Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation
- (2020) Yoav Dori et al. PEDIATRICS
- Pediatric malignancies in neurofibromatosis type 1: a population‐based cohort study
- (2019) Sirkku Peltonen et al. INTERNATIONAL JOURNAL OF CANCER
- Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition
- (2019) Gregor Andelfinger et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
- (2019) Jason Fangusaro et al. LANCET ONCOLOGY
- Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
- (2019) Justin Korfhage et al. MOLECULAR CANCER RESEARCH
- The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin
- (2019) Frank L. Rice et al. PLoS One
- Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells
- (2018) Katarzyna J. Radomska et al. Cancer Discovery
- Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway
- (2018) Zhiguo Chen et al. Cancer Discovery
- Prevalence of neurofibromatosis type 1 in the Finnish population
- (2017) Roope A Kallionpää et al. GENETICS IN MEDICINE
- Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
- (2016) Eva Dombi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The genomic landscape of juvenile myelomonocytic leukemia
- (2015) Elliot Stieglitz et al. NATURE GENETICS
- Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1
- (2015) Edwin Jousma et al. PEDIATRIC BLOOD & CANCER
- Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions
- (2014) Katherine E Schwetye et al. Expert Review of Neurotherapeutics
- RAS diseases in children
- (2014) C. M. Niemeyer HAEMATOLOGICA
- Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
- (2014) B. C. Widemann et al. NEURO-ONCOLOGY
- NF1 Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience
- (2013) Audrey Sabbagh et al. HUMAN MUTATION
- Recommendations for imaging tumor response in neurofibromatosis clinical trials
- (2013) E. Dombi et al. NEUROLOGY
- Injury Signals Cooperate with Nf1 Loss to Relieve the Tumor-Suppressive Environment of Adult Peripheral Nerve
- (2013) Sara Ribeiro et al. Cell Reports
- Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition
- (2012) Carlos E. Prada et al. ACTA NEUROPATHOLOGICA
- Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma
- (2012) D. H. Gutmann et al. GENOME RESEARCH
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
- (2012) Walter J. Jessen et al. JOURNAL OF CLINICAL INVESTIGATION
- Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
- (2012) Kent A Robertson et al. LANCET ONCOLOGY
- Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
- (2012) M. Kolberg et al. NEURO-ONCOLOGY
- Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging
- (2011) Jianqiang Wu et al. PEDIATRIC BLOOD & CANCER
- A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
- (2011) N. Lyubynska et al. Science Translational Medicine
- Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans
- (2010) Elisabeth A. Lasater et al. JOURNAL OF CLINICAL INVESTIGATION
- The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation
- (2009) William E Tidyman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Clinical and Mutational Spectrum of Neurofibromatosis Type 1–like Syndrome
- (2009) Ludwine Messiaen JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing Cells
- (2008) Jianqiang Wu et al. CANCER CELL
- The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
- (2008) Yoko Aoki et al. HUMAN MUTATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started